No Benefit of Hemostatic Drugs on Acute Upper Gastrointestinal Bleeding in Cirrhosis...Asian-Pacific Association for the Study of Liver (APASL) 2020.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • Additional Information
    • Affiliation:
      Department of Gastroenterology, General Hospital of Northern Theater Command (formerly General Hospital of Shenyang Military Area), Shenyang 110840, China
      Postgraduate College, Shenyang Pharmaceutical University, Shenyang 110016, China
      Department of Internal Medicine, Botucatu Medical School, UNESP-Univ Estadual Paulista. Av. Prof. Mário Rubens Guimarães Montenegro, s/n Distrito de Rubião Jr, Botucatu, Brazil
      The Liver Unit and Monarch Liver Lab, Cochin Gastroenterology Group, Ernakulam Medical Center, Kochi, 682028 Kerala, India
      Department of Gastroenterology, The First People's Hospital of Huainan, Huainan 232007, China
      Postgraduate College, Jinzhou Medical University, Jinzhou 121001, China
    • Subject Terms:
    • Subject Terms:
    • Abstract:
      Background and Aims. Acute upper gastrointestinal bleeding (AUGIB) is one of the most life-threatening emergency conditions. Hemostatic drugs are often prescribed to control AUGIB in clinical practice but have not been recommended by major guidelines and consensus. The aim of this study was to investigate the therapeutic effect of hemostatic drugs on AUGIB in cirrhosis. Methods. All cirrhotic patients with AUGIB who were admitted to our hospital from January 2010 to June 2014 were retrospectively included. Patients were divided into hemostatic drugs and no hemostatic drug groups. A 1 : 1 propensity score matching (PSM) analysis was performed by adjusting age, gender, etiology of liver disease, Child-Pugh score, MELD score, hematemesis, red blood cell transfusion, vasoactive drugs, antibiotics, proton pump inhibitors, and endoscopic variceal therapy. Primary outcomes included 5-day rebleeding and in-hospital mortality. Results. Overall, 982 cirrhotic patients with AUGIB were included (870 in hemostatic drugs group and 112 in no hemostatic drug group). In overall analyses, hemostatic drugs group had a significantly higher 5-day rebleeding rate (18.10% versus 5.40%, P = 0.001) than no hemostatic drug group; in-hospital mortality was not significantly different between them (7.10% versus 4.50%, P = 0.293). In PSM analyses, 172 patients were included (86 patients in each group). Hemostatic drugs group still had a significantly higher 5-day rebleeding rate (15.10% versus 5.80%, P = 0.046); in-hospital mortality remained not significantly different (7.00% versus 3.50%, P = 0.304) between them. Statistical results remained in PSM analyses according to the type of hemostatic drugs. Conclusions. The use of hemostatic drugs did not improve the in-hospital outcomes of cirrhotic patients with AUGIB.
    • Journal Subset:
      Biomedical; Peer Reviewed; USA
    • ISSN:
      2314-6133
    • MEDLINE Info:
      NLM UID: 101600173
    • Publication Date:
      20200701
    • Publication Date:
      20200701
    • DOI:
      10.1155/2020/4097170
    • Accession Number:
      144284823
  • Citations
    • ABNT:
      AN, Y. et al. No Benefit of Hemostatic Drugs on Acute Upper Gastrointestinal Bleeding in Cirrhosis...Asian-Pacific Association for the Study of Liver (APASL) 2020. BioMed Research International, [s. l.], p. 1–11, 2020. DOI 10.1155/2020/4097170. Disponível em: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=144284823. Acesso em: 25 set. 2020.
    • AMA:
      An Y, Bai Z, Xu X, et al. No Benefit of Hemostatic Drugs on Acute Upper Gastrointestinal Bleeding in Cirrhosis...Asian-Pacific Association for the Study of Liver (APASL) 2020. BioMed Research International. June 2020:1-11. doi:10.1155/2020/4097170
    • APA:
      An, Y., Bai, Z., Xu, X., Guo, X., Romeiro, F. G., Philips, C. A., Li, Y., Wu, Y., & Qi, X. (2020). No Benefit of Hemostatic Drugs on Acute Upper Gastrointestinal Bleeding in Cirrhosis...Asian-Pacific Association for the Study of Liver (APASL) 2020. BioMed Research International, 1–11. https://doi.org/10.1155/2020/4097170
    • Chicago/Turabian: Author-Date:
      An, Yang, Zhaohui Bai, Xiangbo Xu, Xiaozhong Guo, Fernando Gomes Romeiro, Cyriac Abby Philips, Yingying Li, Yanyan Wu, and Xingshun Qi. 2020. “No Benefit of Hemostatic Drugs on Acute Upper Gastrointestinal Bleeding in Cirrhosis...Asian-Pacific Association for the Study of Liver (APASL) 2020.” BioMed Research International, June, 1–11. doi:10.1155/2020/4097170.
    • Harvard:
      An, Y. et al. (2020) ‘No Benefit of Hemostatic Drugs on Acute Upper Gastrointestinal Bleeding in Cirrhosis...Asian-Pacific Association for the Study of Liver (APASL) 2020’, BioMed Research International, pp. 1–11. doi: 10.1155/2020/4097170.
    • Harvard: Australian:
      An, Y, Bai, Z, Xu, X, Guo, X, Romeiro, FG, Philips, CA, Li, Y, Wu, Y & Qi, X 2020, ‘No Benefit of Hemostatic Drugs on Acute Upper Gastrointestinal Bleeding in Cirrhosis...Asian-Pacific Association for the Study of Liver (APASL) 2020’, BioMed Research International, pp. 1–11, viewed 25 September 2020, .
    • MLA:
      An, Yang, et al. “No Benefit of Hemostatic Drugs on Acute Upper Gastrointestinal Bleeding in Cirrhosis...Asian-Pacific Association for the Study of Liver (APASL) 2020.” BioMed Research International, June 2020, pp. 1–11. EBSCOhost, doi:10.1155/2020/4097170.
    • Chicago/Turabian: Humanities:
      An, Yang, Zhaohui Bai, Xiangbo Xu, Xiaozhong Guo, Fernando Gomes Romeiro, Cyriac Abby Philips, Yingying Li, Yanyan Wu, and Xingshun Qi. “No Benefit of Hemostatic Drugs on Acute Upper Gastrointestinal Bleeding in Cirrhosis...Asian-Pacific Association for the Study of Liver (APASL) 2020.” BioMed Research International, June 27, 2020, 1–11. doi:10.1155/2020/4097170.
    • Vancouver/ICMJE:
      An Y, Bai Z, Xu X, Guo X, Romeiro FG, Philips CA, et al. No Benefit of Hemostatic Drugs on Acute Upper Gastrointestinal Bleeding in Cirrhosis...Asian-Pacific Association for the Study of Liver (APASL) 2020. BioMed Research International [Internet]. 2020 Jun 27 [cited 2020 Sep 25];1–11. Available from: http://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=rzh&AN=144284823